From Financial Modeling Prep: 2025-03-12 07:00:02

Chimerix, Inc. (NASDAQ: CMRX) has a stable consensus price target of $8.55, with analysts confident in the company’s future. Potential approval for dordaviprone could lead to over $1 billion in U.S. revenue. The Phase 3 ACTION study’s interim data readout in Q3 2025 is a crucial event that may impact investor sentiment and price targets.



Read more at Financial Modeling Prep:: Chimerix, Inc. (NASDAQ: CMRX) Overview: A Biopharmaceutical Innovator on the Verge of a Breakthrough